Breaking News, Collaborations & Alliances

Horizon, Glenmark Sign Biomfg. License Agreement

For GS knockout CHO cell line for manufacture of biotherapeutics

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Horizon Discovery Group, a global provider of gene editing and gene modulation for cell line engineering, announced the full commercial licensing to Glenmark Pharmaceuticals of its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line. Terms of the agreement were based on stringent evaluation of the cell line by Glenmark to assess its suitability for adoption into the company’s biomanufacturing processes.   “After extensive evaluation, Horizon’s GS knockout CHO ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters